S 646240

Drug Profile

S 646240

Alternative Names: S-646240

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator OncoTherapy Science; Shionogi
  • Class Eye disorder therapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 02 Feb 2016 Discontinued - Phase-II for Age-related macular degeneration in Japan (SC)
  • 23 Jul 2015 Phase-IIa is ongoing for Age-related macular degeneration in Japan
  • 01 Dec 2014 Shionogi completes a phase II trial in Age-related macular degeneration in Japan (UMIN000008040)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top